RCS - Ondine Biomedical - First Mexican Hospital Steriwave Deployment

Ondine BiomedicalAnnouncement

Wed 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250813:nRSM1760Va&default-theme=true

RNS Number : 1760V  Ondine Biomedical Inc.  13 August 2025

13 August 2025

RNS

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

First Mexican Hospital Steriwave Deployment

Ondine Biomedical Launches ABC Medical Center Pilot of Steriwave® Nasal
Photodisinfection

Ondine Biomedical Inc. (AIM: OBI) announces the American British Cowdray
("ABC") Medical Center in Mexico City will begin piloting Steriwave(®) nasal
photodisinfection system in September. This marks the first hospital
deployment of Steriwave in Mexico and will target the reduction of surgical
site infections (SSIs) and healthcare-associated infections (HAIs) in
orthopedic and neurosurgery patients.

With a population of approximately 132 million, Mexico's healthcare system is
anchored by its private sector, which comprises approximately 3,000 private
hospitals which perform around 25% of all surgeries annually. This private
sector is crucial for high-income citizens and the thriving medical tourism
industry, which attracts over 1.3 million international patients annually. A
key challenge facing this sector is the high rate of surgical site infections
(SSIs), which are nearly double those in the U.S. This issue is compounded by
rising antimicrobial resistance (AMR), making advanced infection control a
critical priority for hospitals, surgery centers, and clinics that serve this
valuable market.

Carolyn Cross, CEO of Ondine, said:

"The Mexican market is a key pillar of our long-term strategic growth plans,
and we are thrilled to partner with a world-class institution in ABC Medical
Center. Their dedication to clinical excellence and patient safety makes them
the ideal pilot partner for Steriwave's initiation in Mexico. This
collaboration is a vital step in introducing our validated, non-antibiotic
solution to a large market where combatting rising multidrug resistance is a
top priority."

Dra. Roxana Trejo Gonzalez, Director of Infection Control at the ABC Medical
Center, President of the Mexican Association for the Study of Nosocomial
Infections (AMEXPE) and Co-founder of the Latin American Association for
Infection Control (ASLACI) commented:

"Piloting Steriwave as a first in Mexico reflects our commitment to adopting
evidence-based interventions against antimicrobial resistance. Reducing nasal
pathogen load is a crucial step in preventing SSIs and protecting our local
and international patients."

Steriwave has been deployed in leading hospitals in Canada, the UK, and other
jurisdictions, with studies showing significant reductions in HAIs and no
evidence of microbial resistance development. Steriwave is a non-antibiotic,
light-activated therapy that decolonizes the nasal passages, a primary
reservoir for multidrug-resistant organisms. The procedure involves applying a
proprietary photosensitizer into the nares, followed by illumination with red
light. This photochemical reaction generates singlet oxygen, rapidly
inactivating bacteria, viruses, and fungi, without contributing to AMR.

 

About ABC Medical Center

Established in 1886, ABC Medical Center is a premier private healthcare
provider in Mexico, operating two campuses with 850 beds. The institution is
recognized for its advanced surgical programs, rigorous infection prevention
protocols, and commitment to adopting innovative medical technologies to
enhance patient outcomes.

 

 Enquiries:

 Ondine Biomedical Inc.                                     www.ondinebio.com (http://www.ondinebio.com)
 Carolyn Cross, CEO                                         +1 604 669 0555

or via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                              +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                              +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                           +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPJMLTMTABMMA